



(51) International Patent Classification:

C07D 235/26 (2006.01) *A61P 25/20* (2006.01)
C07D 235/28 (2006.01) *A61P 25/22* (2006.01)
A61K 31/4184 (2006.01) *A61P 25/24* (2006.01)

(21) International Application Number:

PCT/BR2017/050320

(22) International Filing Date:

23 October 2017 (23.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

BR1020160248140 24 October 2016 (24.10.2016) BR

(71) Applicant: **ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A.** [BR/BR]; ROD. PRESIDENTE DUTRA, KM 222.2 - PORTO DA IGREJA, 07034-904 Guarulhos (BR).

(72) Inventors: **RUCH WERNECK GUIMARÃES, Cristiano**; Alameda dos Anapurus, 883 Apto 131 Bloco B, 04087-002 São Paulo (BR). **FELYPE ZANETI DE**

AZEVEDO, Hatylas; Rua Fábila, 138 Apto 81 Bloco B, 05051-030 São Paulo (BR). **MASCARELLO, Alessandra**; Rua Santa Izabel 451 Apto 138 Torre 1, 07023-022 Guarulhos (BR). **WATANABE DA COSTA, Renata**; Rua Amélia Perpétua 92, 02040-100 São Paulo (BR). **FREIRE TORRES RUSSO, Valter**; Rua Benedito Martins 270, 13975-020 Itapira (BR). **MANNOCHIO DE SOUZA RUSSO, Elisa**; Rua Benedito Martins 270, 13975-020 Itapira (BR).

(74) Agent: **GAJARSA, Lucas Martins**; Rua Raul Pompéia 617 - Pompéia, 05025-0010 São Paulo (BR).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS




FIG. 1

(57) Abstract: The present invention relates to novel and inventive pharmacologically active benzimidazole derivative compounds, which surprisingly have high affinity for melatonin MT₁ and MT₂ receptors and low affinity for CYP450 complex enzymes f specially CYP1A2. The present, invention also relates to novel and inventive routes of synthesis of these compounds, pharmaceutical compositions comprising the compounds and the use of these compounds in the treatment of individuals affected by psychiatric disorders and/or sleep disorders related to these receptors (specially depression, anxiety, circadian cycle disorders), in addition to process for producing the composition.



SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))